Central nervous system (CNS) toxicities of antiretroviral therapies are well described. Functional MRI (fMRI) can assess brain activity and functional connectivity (FC) non-invasively, providing insights into pathogenic mechanisms. We assessed changes in fMRI patterns in neurologically asymptomatic people with HIV (PWH) participating in two studies assessing CNS parameters when switching antiretroviral therapy.
Virologically suppressed PWH switching from tenofovir-DF/emtricitabine (TDF/F) with efavirenz to rilpivirine (n=10) and TDF/F with raltegravir to dolutegravir (n=12) were included. Changes in CNS parameters included patient-reported outcome measures (PROM) of sleep (PSQI) and depression (HADS). fMRI imaging was assessed at baseline and at least 120 days after switching therapy and included resting-state fMRI (RS-fMRI) and behavioral stop signal reaction times (SSRT) task fMRI. Resting state and SSRT fMRI were examined by independent component analyses (ICA) using the FSL’s MELODIC tool.
Of 22 participants, all were male, median age (range) was 49 (33-71) years, median CD4+count (range) was 700 (339-1164) cells/uL and HIV RNA was less than <20 copies/mL in all. Switching from efavirenz to rilpivirine was associated with enhanced connectivity of the Dorsal Attention Network (DAN) most pronounced in the right superior parietal lobule and a reduction in stop SSRTs (response inhibition, p=0.025, see figure) which was positively correlated with the duration of time previously on efavirenz (median 5 (range 1-10) years, p=0.02). Switching from raltegravir to dolutegravir was associated with increased connectivity in the DAN, sensory-motor (SM), and associative visual (VISAS) networks. There was a 4.8% decline in anxiety scores on HADS and a 2% decline in sleep symptoms on PSQI, with scores of 19 and 14, and 22 and 20 at baseline and follow-up, respectively, after switching from efavirenz to rilpivirine (p<0.005) and no significant changes in PROMS when switching from raltegravir to dolutegravir. No association between changes in fMRI and PROMs were observed.
In PWH switching antiretroviral therapy, changes in fMRI are evident. This was most pronounced in PWH switching from efavirenz to rilpivirine where improved attention and response inhibition on fMRI was evident. Whilst changes were evident on fMRI when switching integrase inhibitor, any clinical implications of these findings require further validation.